Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2000-11-02
2008-05-13
Yaen, Christopher H. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07371376
ABSTRACT:
Anti-ErbB2 antibodies are described which bind to an epitope in Domain 1 of ErbB2 and induce cell death via apoptosis. Various uses for these antibodies are also described.
REFERENCES:
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4943533 (1990-07-01), Mendelsohn et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5169774 (1992-12-01), Frankel et al.
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5288477 (1994-02-01), Bacus
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5464751 (1995-11-01), Greene et al.
patent: 5480968 (1996-01-01), Kraus et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5571894 (1996-11-01), Wels et al.
patent: 5578482 (1996-11-01), Lippman et al.
patent: 5587458 (1996-12-01), King et al.
patent: 5604107 (1997-02-01), Carney et al.
patent: 5641869 (1997-06-01), Vandlen et al.
patent: 5663144 (1997-09-01), Greene et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5705157 (1998-01-01), Greene
patent: 5720937 (1998-02-01), Hudziak et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5730977 (1998-03-01), Ooka et al.
patent: 5747261 (1998-05-01), King et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5783404 (1998-07-01), Koski
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5804396 (1998-09-01), Plowman
patent: 5821337 (1998-10-01), Carter et al.
patent: 5824311 (1998-10-01), Greene et al.
patent: 5834229 (1998-11-01), Vandlen et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5837523 (1998-11-01), Greene et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5846749 (1998-12-01), Slamon et al.
patent: 5856089 (1999-01-01), Wang et al.
patent: 5856110 (1999-01-01), Vandlen et al.
patent: 5859206 (1999-01-01), Vandlen et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 5908835 (1999-06-01), Bissery
patent: 5910486 (1999-06-01), Curiel et al.
patent: 5922845 (1999-07-01), Deo et al.
patent: 5925519 (1999-07-01), Jensen et al.
patent: 5939531 (1999-08-01), Wels et al.
patent: 5955311 (1999-09-01), Rockwell et al.
patent: 5977322 (1999-11-01), Marks et al.
patent: 5985553 (1999-11-01), King et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6028059 (2000-02-01), Curiel et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6123939 (2000-09-01), Shawver et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 6270765 (2001-08-01), Deo et al.
patent: 6387371 (2002-05-01), Hudziak et al.
patent: 6395272 (2002-05-01), Deo et al.
patent: 6399063 (2002-06-01), Hudziak et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6458356 (2002-10-01), Arakawa et al.
patent: 6512097 (2003-01-01), Marks et al.
patent: 2002/0155527 (2002-10-01), Stuart et al.
patent: 505148 (1992-09-01), None
patent: 599274 (1994-06-01), None
patent: 616812 (1994-09-01), None
patent: 656367 (1995-06-01), None
patent: 412116 (1995-11-01), None
patent: 494135 (1996-04-01), None
patent: 502812 (1996-08-01), None
patent: 711565 (1998-08-01), None
patent: 554441 (1999-01-01), None
patent: 1006194 (2000-06-01), None
patent: 444181 (2001-10-01), None
patent: 95006982 (1987-05-01), None
patent: 2761543 (1990-06-01), None
patent: 2895105 (1991-08-01), None
patent: 3-240498 (1991-10-01), None
patent: 5-117165 (1993-05-01), None
patent: 5-170667 (1993-07-01), None
patent: 5-213775 (1993-08-01), None
patent: 5-317084 (1993-12-01), None
patent: 7-59588 (1995-03-01), None
patent: WO87/07646 (1987-12-01), None
patent: WO89/06692 (1989-07-01), None
patent: WO89/10412 (1989-11-01), None
patent: WO91/02062 (1991-02-01), None
patent: WO91/05264 (1991-04-01), None
patent: WO92/10573 (1992-06-01), None
patent: WO92/22653 (1992-12-01), None
patent: WO93/03741 (1993-03-01), None
patent: WO93/12220 (1993-06-01), None
patent: WO93/16185 (1993-08-01), None
patent: WO93/21232 (1993-10-01), None
patent: WO93/21319 (1993-10-01), None
patent: WO94/00136 (1994-01-01), None
patent: WO94/10202 (1994-05-01), None
patent: WO94/22478 (1994-10-01), None
patent: WO94/28127 (1994-12-01), None
patent: WO95/16051 (1995-06-01), None
patent: WO95/17507 (1995-06-01), None
patent: WO95/28485 (1995-10-01), None
patent: WO96/07321 (1996-03-01), None
patent: WO96/16673 (1996-06-01), None
patent: WO96/18409 (1996-06-01), None
patent: WO96/30046 (1996-10-01), None
patent: WO96/32480 (1996-10-01), None
patent: WO96/40789 (1996-12-01), None
patent: WO97/00271 (1997-01-01), None
patent: WO97/04801 (1997-02-01), None
patent: WO97/20858 (1997-06-01), None
patent: WO97/27848 (1997-08-01), None
patent: WO97/38731 (1997-10-01), None
patent: WO98/02463 (1998-01-01), None
patent: WO98/18489 (1998-05-01), None
patent: WO98/45331 (1998-10-01), None
patent: WO98/45479 (1998-10-01), None
patent: WO99/31140 (1999-06-01), None
Seaver S (Genetic Engineering News Aug. 1994; 14(14):10&21).
(J. Pharm. Pharmacol. Oct. 1995;47(10):870-875).
Lewis et al—Cancer Immunol. Immunother. 1993;37:255-263.
U.S. Appl. No. 08/948,149, filed Sep. 10, 1997, Fendly et al.
U.S. Appl. No. 09/119,152, filed Jul. 20, 1998, Fendly et al.
U.S. Appl. No. 09/266,706, filed Nov. 3, 1999, Fendly et al.
Aasland et al., “Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2
eu and c-erbB”British Journal of Cancer57(4):358-363 (Apr. 1988).
Adams and Weiner, “Intracellular single-chain Fv antibodies—a knockout punch for neoplastic cells?”Gynecologic Oncology59(1):6-7 (Oct. 1995).
Arboleda et al., “Effects of the 4D5 antibody on HER2
eu heterodimerization with other class I receptors in human breast cancer cells”Proceedings of the American Association for Cancer Research(Abstract #353) 37:51 (Mar. 1996).
Arteaga et al., “p185c-erbB-2Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair”Cancer Research54(14):3758-3765 (Jul. 15, 1994).
Bacus et al., “Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2
eu Antigen”Molecular Carcinogenesis3(6):350-362 (1990).
Bacus et al., “Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells”Cancer Research52(9):2580-2589 (May 1, 1992).
Baselga et al., “Anti HER2 Humanized Monoclonal Antibody (MAb) Alone and in Combination with Chemotherapy Against Human Breast Carcinoma Xenografts”Proceedings of ASCO-13th Annual Meeting(Abstract #53), Dallas, TX 13:63 (Mar. 1994).
Baselga et al., “HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications”Oncology11(3 Suppl 2):43-48 (Mar. 1997).
Baselga et al., “Monoclonal antibodies directed against growth factor receptors enhance the efficacy of chemotherapeutic agents”Annals of Oncology(abstract #010) 5(Suppl. 5) (1994).
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer”J. Clin. Oncol.14(3):737-744 (Mar. 1996).
Baselga et al., “Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy”Pharmac. Ther.64:127-154 (1994).
Baselga et al., “Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enchances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
eu Overexpessing Human Breast Cancer Xenografts”Cancer Research58:2825-2831 (Jul
Genentech Inc.
Lee Wendy M.
Yaen Christopher H.
LandOfFree
Anti-ErbB2 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-ErbB2 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-ErbB2 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3982174